4 research outputs found
Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial
<p></p><p><b>Article full text</b></p><p><br></p><p>The full text of this article can
be found here<b>. </b><u>https://link.springer.com/article/10.1007/s13300-018-0437-x</u></p><p><u><br></u></p><p><b>Provide enhanced content for this
article</b></p><p><br></p><p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âÂÂmailto:[email protected]âÂÂ"><b>[email protected]</b></a>.</p><p><br></p><p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include,
but are not limited to:</p><p><br></p><p>⢠Slide decks</p><p>⢠Videos and animations</p><p>⢠Audio abstracts</p><p>
</p><p>⢠Audio slides</p><p></p
The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0267-2"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional enhanced
digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides<u></u></p>
<p> </p>
<p> </p>
<p> </p>
<p> </p>
<p> </p
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0292-1"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced content for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced content for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as âpeer reviewedâ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides</p>
<p> </p>
<p> </p>
<p> </p>
<p> </p>
<p> </p
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0292-1"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced content for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced content for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as âpeer reviewedâ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides</p>
<p> </p